Want to see IN:BIOFILCHEM full AI Analyst Report?
Top Page
Biofil Chemicals & Pharmaceuticals Ltd.
(BIOFILCHEM)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹29.00
▼(-9.32% Downside)
Action:Reiterated
Date:09/11/26
The score is held back primarily by weak financial performance—especially inconsistent and often negative operating/free cash flow alongside falling margins and a sharp 2026 revenue decline. Technicals are supportive (price above key moving averages with a positive MACD), but the elevated RSI points to potential near-term froth. Valuation further constrains the score given the very high P/E and no dividend yield data to offset it.
Positive Factors
Conservative Leverage
Modest leverage gives Biofil greater financial flexibility than a heavily indebted operator, reducing fixed financing pressure and leaving more capacity to manage volatility. Although debt rose in 2026, the overall balance-sheet position remains a supportive foundation if operations stabilize.
Negative Factors
Sharp Revenue Decline
The steep 2026 revenue contraction highlights limited top-line visibility and makes it harder to sustain operating scale. A smaller revenue base can reduce absorption of fixed costs, constrain reinvestment, and weaken the company’s ability to build consistent earnings over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Leverage
Modest leverage gives Biofil greater financial flexibility than a heavily indebted operator, reducing fixed financing pressure and leaving more capacity to manage volatility. Although debt rose in 2026, the overall balance-sheet position remains a supportive foundation if operations stabilize.
Read all positive factors
Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹482.36M
Dividend YieldN/A
Average Volume (3M)33.45K
Price to Earnings (P/E)98.6
Beta (1Y)1.47
Revenue Growth9.31%
EPS Growth-82.71%
CountryIN
Employees24
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.30
Shares Outstanding16,273,800
10 Day Avg. Volume2,116
30 Day Avg. Volume33,455
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.95
Price to Sales (P/S)1.48
P/FCF Ratio-51.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biofil Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Biofil Chemicals and Pharmaceuticals Limited, headquartered in Indore, India, is primarily involved in the country's pharmaceutical and chemical industries. This company supplies a comprehensive array of fundamental drugs and chemical compounds, i...
How the Company Makes Money
Detailed, company-specific information on Biofil Chemicals & Pharmaceuticals Ltd.’s revenue model (e.g., primary product lines, customer segments, sales channels, and material partnerships) is not available from the provided prompt, so a factual e...
Biofil Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 343.13M | 283.95M | 334.02M | 400.35M | 300.35M | 223.82M |
| Gross Profit | 14.20M | 10.37M | 20.91M | 25.28M | 25.63M | 28.66M |
| EBITDA | 9.56M | 37.32M | 11.53M | 13.06M | 12.65M | 14.83M |
| Net Income | 4.84M | 27.86M | 5.58M | 7.09M | 5.60M | 6.98M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 428.48M | 509.60M | 470.83M | 314.06M | 187.32M |
| Cash, Cash Equivalents and Short-Term Investments | 33.26M | 33.26M | 2.55M | 22.84M | 377.00K | 1.45M |
| Total Debt | 0.00 | 30.20M | 4.71M | 4.39M | 5.22M | 4.65M |
| Total Liabilities | -215.64M | 212.84M | 321.79M | 288.80M | 141.04M | 18.95M |
| Stockholders Equity | 215.64M | 215.64M | 187.82M | 182.03M | 173.01M | 168.38M |
Cash Flow | ||||||
| Free Cash Flow | -36.36M | -8.15M | -20.24M | 23.71M | -1.22M | -2.90M |
| Operating Cash Flow | -35.65M | -6.15M | -19.24M | 23.94M | -1.12M | -2.20M |
| Investing Cash Flow | 41.30M | 11.37M | -1.00M | -229.00K | -106.00K | -699.00K |
| Financing Cash Flow | -4.61M | 25.49M | -45.00K | -1.25M | 151.00K | -58.00K |
Biofil Chemicals & Pharmaceuticals Ltd. Technical Analysis
Negative
31.98
Price Trends
32.31
Negative
33.29
Negative
33.11
Negative
Market Momentum
-0.46
Positive
36.01
Neutral
11.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOFILCHEM, the sentiment is Negative. The current price of 31.98 is below the 20-day moving average (MA) of 32.40, below the 50-day MA of 32.31, and below the 200-day MA of 33.11, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 36.01 is Neutral, neither overbought nor oversold. The STOCH value of 11.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOFILCHEM.
Biofil Chemicals & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.53B | 10.61 | ― | 0.70% | 4.29% | 2.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹459.02M | -1.22 | ― | 0.28% | -22.27% | -291.72% | |
49 Neutral | ₹1.50B | -10.03 | ― | ― | -29.72% | 47.98% | |
47 Neutral | ₹482.36M | 98.61 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹465.15M | -0.27 | ― | 0.67% | -39.80% | -452.04% | |
42 Neutral | ₹284.07M | -1.70 | ― | 0.67% | -95.17% | 50.07% |
* General Sector Average
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
29.64
-11.49
-27.94%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
69.40
-1.60
-2.25%
IN:LASA
Lasa Supergenerics Ltd.
5.67
-5.88
-50.91%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
29.00
-43.10
-59.78%
IN:PAR
Par Drugs and Chemicals Limited
123.95
17.40
16.33%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.61
0.71
14.49%
Biofil Chemicals & Pharmaceuticals Ltd. Corporate Events
Biofil Chemicals Announces Virtual AGM and Remote E-Voting Details
Aug 28, 2026
Biofil Chemicals Pharmaceuticals Ltd. has published newspaper advertisements announcing its 41st Annual General Meeting, scheduled for 23 September 2026, which will be conducted via video conferencing and other audio-visual means. The notices, ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.